TrialInternational journal of colorectal disease2017

Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma.

Fernando Rivera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.